Immune checkpoint inhibition in gastric cancer: A systematic review

den Hoed, 2016, Gastric cancer: how can we reduce the incidence of this disease?, Curr Gastroenterol Rep, 18, 34, 10.1007/s11894-016-0506-0 Jemal, 2010, Global patterns of cancer incidence and mortality rates and trends, Cancer Epidemiol Biomark Prev, 19, 1893, 10.1158/1055-9965.EPI-10-0437 Wagner, 2017, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 8, CD004064 Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3 Kei, 2015, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012, J Clin Oncol, 33 Muro, 2015, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012, Gastrointest Canc Symp, 1996, 53 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Schachter, 2017, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), Lancet, 390, 1853, 10.1016/S0140-6736(17)31601-X Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Moher, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst Rev, 4, 1, 10.1186/2046-4053-4-1 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Neil Howard, 2014, Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody, J Clin Oncol, 32, 3002, 10.1200/jco.2014.32.15_suppl.3002 Roy, 2013, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors, J Clin Oncol, 31, 3000, 10.1200/jco.2013.31.15_suppl.3000 Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 390, 2461, 10.1016/S0140-6736(17)31827-5 Bang, 2017, Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer, Clin Cancer Res., 23, 5671, 10.1158/1078-0432.CCR-17-0025 Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Li, 2017, Should nivolumab-induced colitis Be treated by infliximab?, Clin Gastroenterol Hepatol, 15, 1637, 10.1016/j.cgh.2017.05.012 Patel, 2016, Expression of programmed death-ligand 1 (PD-L1), mismatch repair status, and Epstein-Barr status in locally advanced gastric adenocarcinoma: correlation to clinical outcome, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.e15526 Chung, 2016, Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer, J Clin Oncol, 34, 167, 10.1200/jco.2016.34.4_suppl.167 Muro, 2015, Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012, J Clin Oncol, 33, 3, 10.1200/jco.2015.33.3_suppl.3 Bang, 2015, Relationship between PDL1 expression and clinical outcomes in patients with advanced gastric cancer treated with the antiPD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012, J Clin Oncol, 33, 4001, 10.1200/jco.2015.33.15_suppl.4001 Ohtsu, 2015, Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: randomized, open-label, phase 3 KEYNOTE-061 study, Ann Oncol, 26, 69 Muro, 2015, Clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) in KEYNOTE-012, Ann Oncol, 26, vii12, 10.1093/annonc/mdv406.03 Bang, 2015, Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012, Ann Oncol, 26, iv118, 10.1093/annonc/mdv262.04 Fuchs, 2016, Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, J Clin Oncol, 34, 10.1200/jco.2016.34.4_suppl.tps184 Fuchs, 2015, Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: the phase 2 KEYNOTE-059 study, Ann Oncol, 26, 347, 10.1093/annonc/mdv233.105 Ayers, 2015, Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors, J Immunother Cancer, 3, P80, 10.1186/2051-1426-3-S2-P80 Oh, 2016, Avelumab (MSB0010718C), an anti-PD-LI antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: a phase Ib JAVELIN Solid Tumor trial, J Clin Oncol, 34, 10.1200/jco.2016.34.4_suppl.tps188 Kelly, 2015, Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma, J Immunother Cancer, 3, P157, 10.1186/2051-1426-3-S2-P157 Lutzky, 2014, A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors, J Clin Oncol, 32, 3001, 10.1200/jco.2014.32.15_suppl.3001 Hodi, 2013, MPDL3280A (anti-PDL1): clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors, Eur J Cancer, 49, S184 Kohrt, 2013, Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1, J Immunother Cancer, 1, 012, 10.1186/2051-1426-1-S1-O12 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Roy, 2016, A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): phase 1a results, J Clin Oncol, 34, 3056, 10.1200/JCO.2016.34.15_suppl.3056 Gold P, Harvey RD, Spira A, Bazhenova L, Nemunaitis J, Baranda J, et al. P3.02c-011 a phase 1b open-label study of PEGPH20 combined with pembrolizumab in patients with selected Hyaluronan-high solid tumors. J Thorac Oncol. 12(1):S1278. Zev, 2016, Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors, J Clin Oncol, 34 Karen, 2016, Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial, J Clin Oncol, 34, 3055, 10.1200/JCO.2016.34.15_suppl.3055 Yasuhide, 2015, A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer, J Clin Oncol, 33, 4047, 10.1200/jco.2015.33.15_suppl.4047 Howard, 2017, Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC), J Clin Oncol, 35, 673, 10.1200/JCO.2017.35.4_suppl.673 David, 2016, Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study, J Clin Oncol, 34, 833, 10.1200/JCO.2015.63.7421 Spahn, 2015, Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models, J. Immunother. Cancer, 3, P303, 10.1186/2051-1426-3-S2-P303 Kelly, 2015, Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma, J. Immunother. Cancer, 3, P157, 10.1186/2051-1426-3-S2-P157 Wolchok, 2013, Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma, Ann N Y Acad Sci, 1291, 1, 10.1111/nyas.12180 Antonia, 2016, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, Lancet Oncol, 17, 883, 10.1016/S1470-2045(16)30098-5 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Josep, 2016, KEYNOTE-062: phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, J Clin Oncol, 34 Atsushi, 2016, Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: phase 3 KEYNOTE-061 study, J Clin Oncol, 34